• Coronavirus pandemic

Condom gel compound proves effective against COVID-19

Starpharma is hoping to re-purpose its antiviral compound used in its condom and vaginal gels to create a COVID-19 preventative nasal spray or eye drops.

• Apr 16, 2020
• Yolanda Redrup

• BOSS

The CEO who swears by a sleeping pill on plane trips

Starpharma CEO Jackie Fairley believes that if there are pharmaceuticals that work well, why not use them?

• Mar 4, 2020
• Patrick Durkin

Australian biotech Starpharma approved to sell antiviral condoms in Japan

Australian biotechnology company Starpharma will start selling its antiviral VivaGel condoms in one of the world's largest condom markets after receiving final regulatory approval on Wednesday.

• Jan 2, 2019

Election 2016: CSIRO Manufacturing wrote Turnbull's script

CSIRO Manufacturing's partnership with Boron Molecular is the kind of industry-research collaboration the PM wants to nurture.

• Updated Jun 15, 2016
• Ben Potter

Biotech Starpharma rises 6pc on Zika virus product

Melbourne-based Starpharma's stock rose 6pc after tests showed its anti-viral gel could stop sexual transmission of the epidemic.

• Updated May 5, 2016
• Tim Binsted

Biotech stocks to get the heart racing … or slowing

Notoriously volatile and tricky to pick, biotechnology stocks gave nimble investors plenty of opportunity to outperform blue chips in 2015 and are set to provide some wild rides in 2016 too.

• Updated Jan 7, 2016
• Jessica Sier

Starpharma impresses

The AstraZeneca partnership and trial results are all "encouraging'.

• Updated Dec 3, 2015
• Elise Shaw

Starpharma patent granted

The new patent strengthens and expands the patent protection on the VivaGel BV product.

• Updated Oct 15, 2015
• Elise Shaw

Starpharma product approval 'precursor to deal'

This approval is an important milestone for the company as it marks the first approval received for VivaGel for the Bacterial Vaginosis application.

• Updated Sep 28, 2015
• Elise Shaw

Starpharma signs deal with AstraZeneca on drug delivery technology

Starpharma has inked a deal with pharmaceutical giant AstraZeneca that could be worth more than $US450 million ($650 million) a drug developed using its drug delivery technology. Its shares jumped 22 per cent on the news.

• Updated Sep 7, 2015
• Tim Binsted

• Pharmaceuticals

Essential services look set for healthy returns this year

Depending on the theme investors wish to tap into there is good value among small cap healthcare and services companies. In what is shaping up as a tricky year on the sharemarket companies exposed to essential services are likely to be well supported.

• Jan 28, 2015
• Trevor Hoey

• Pharmaceuticals

Low Aussie dollar could spur biotech takeovers

A string of high-profile setbacks may have whittled away support for biotechnology companies, but executives and analysts say there is still plenty of money from overseas and the weak Australian dollar may spur a series of takeovers by foreign buyers.

• Updated Jan 12, 2015
• Jessica Gardner

• Market Wrap

Starpharma ready to slip lubricated condom into market

Starpharma’s VivaGel condom is a world-first product and the only condom of its type that provides barrier protection and incorporates a proprietary anti-viral compound

• Oct 27, 2014
• Trevor Hoey

• Investment banking

Starpharma looks to raise up to $15 million

Starpharma is seeking to raise between $10 million and $15 million via a placement and share purchase plan managed by Bell Potter Securities.

• Updated Sep 18, 2014
• Sarah Thompson, Anthony Macdonald and Jake Mitchell

• Market Wrap

Starpharma, FDA agree to trials for VivaGel

Starpharma agreement with US authorities over clinical studies of a medical gel take the group’s product one critical step closer to a regulatory submission for approval in the US.

• Updated Jul 14, 2014
• Trevor Hoey